Recent Price Movement and Market Context
On 8 December 2025, Piramal Pharma’s stock price reached an intraday low of Rs.176.35, representing a 2.0% fall on the day and underperforming its sector by 1.42%. Over the past four trading sessions, the stock has declined by 4.67%, signalling sustained downward momentum. This movement places the stock well below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a persistent bearish trend in the short to long term.
In contrast, the broader market index, Sensex, experienced a negative session, closing at 85,393.16 points, down 0.37% from the previous close. Despite this, Sensex remains close to its 52-week high of 86,159.02, trading above its 50-day and 200-day moving averages, which suggests a generally bullish market environment that Piramal Pharma has not mirrored.
Performance Over the Past Year
Over the last 12 months, Piramal Pharma’s stock has recorded a return of -33.90%, significantly lagging behind the Sensex’s positive return of 4.52% during the same period. The stock’s 52-week high was Rs.273.20, highlighting the extent of the decline to the current low. This underperformance extends beyond the last year, with the stock also trailing the BSE500 index over the past three years, one year, and three months.
This week's disclosed pick, a Large Cap from NBFC, comes with precise Target Price and analysis. Check if you're positioned right for this opportunity!
- - Precise target price set
- - Weekly selection live
- - Position check opportunity
Financial Indicators and Profitability
Piramal Pharma’s recent quarterly results reveal a challenging financial landscape. The Profit Before Tax (PBT) excluding other income stood at a loss of Rs.111.78 crore, reflecting a decline of 340.0% compared to the previous four-quarter average. Similarly, the Profit After Tax (PAT) recorded a loss of Rs.99.22 crore, down by 613.2% relative to the same benchmark. Net sales for the quarter were Rs.2,043.72 crore, showing a reduction of 10.5% against the previous four-quarter average.
These figures highlight a contraction in profitability and sales in the near term. The company’s ability to generate returns on shareholders’ equity remains subdued, with an average Return on Equity (ROE) of 0.32%, indicating limited profitability per unit of shareholder funds.
Debt and Valuation Metrics
One of the key concerns for Piramal Pharma is its elevated debt level relative to earnings. The Debt to EBITDA ratio stands at 3.83 times, suggesting a relatively high leverage position that may constrain financial flexibility. Despite this, the company’s Return on Capital Employed (ROCE) is recorded at 2.7%, and the Enterprise Value to Capital Employed ratio is 2.3, which points to a valuation that is fair when compared to peers.
Operating profit has shown a compound annual growth rate of 23.29% over the long term, indicating some strength in core business operations despite recent setbacks. However, profits over the past year have declined by 158.7%, underscoring the volatility in earnings performance.
Institutional Holdings and Market Position
Institutional investors hold a significant stake in Piramal Pharma, accounting for 45.17% of the shareholding. This level of institutional ownership reflects a considerable presence of entities with extensive resources and analytical capabilities monitoring the company’s fundamentals.
Piramal Pharma or something better? Our SwitchER feature analyzes this small-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Sector and Market Comparison
Within the Pharmaceuticals & Biotechnology sector, Piramal Pharma’s recent performance contrasts with the broader market’s relative stability. While the Sensex trades near its 52-week high and maintains bullish moving averages, Piramal Pharma’s stock remains below all key moving averages, reflecting a divergence from the general market trend.
The stock’s current valuation is discounted compared to the historical averages of its peers, which may reflect the market’s assessment of the company’s financial position and recent earnings volatility.
Summary of Key Price and Performance Data
To summarise, Piramal Pharma’s stock has reached a 52-week low of Rs.176.35, down from its high of Rs.273.20 within the last year. The stock’s four-day losing streak has resulted in a cumulative decline of 4.67%. The company’s financial results for the recent quarter show losses in both PBT and PAT, alongside a reduction in net sales. Debt levels remain elevated relative to earnings, and profitability metrics such as ROE and ROCE indicate modest returns on capital.
Despite these challenges, operating profit growth over the long term and fair valuation metrics provide context to the company’s current position within the Pharmaceuticals & Biotechnology sector.
Get 1 year of Weekly Picks FREE when you subscribe to MojoOne. Offer ends soon. Start Saving Now →
